Corline Biomedical

Focus: Corline Biomedical is a newly founded (2024) Swedish biotech company focused on heparin aggregate technology for metabolic diseases and transplantation applications. The company is in early-stage development with a minimal public footprint and no established market position.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Corline Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow Corline Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Transplantation of islets with heparin coating

Type 1 Diabetes Mellitus

N/A

Clinical Trials (1)

NCT00678990Heparinized Islets in Clinical Islet Transplantation

N/A

Help build intelligence for Corline Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public company with novel heparin-based platform technology addressing unmet needs in transplantation and metabolic disease
Focus on high-impact indications (delayed graft function, Type 1 diabetes) with potential for meaningful clinical differentiation
Location in Uppsala, Sweden provides access to strong academic biotech ecosystem and European regulatory pathways

Watch Out For

Extreme early-stage risk: only 1 Phase 1 program and 1 preclinical program; no revenue, no approved products, and zero active job openings indicate minimal operational infrastructure
Severe organizational immaturity: founded in 2024 with unknown employee count, no disclosed funding, and public listing status unclear—significant execution and capital risk
No hiring activity suggests company may be in stealth/planning phase or facing delayed scaling; limited visibility into team size, scientific leadership, and development timeline

Generated by Claude from Corline Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Renaparin

Delayed Graft Function

Phase 1

Clinical Trials (1)

NCT03773211Renaparin® in Kidney Transplantation

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 2 clinical trials

Top TAs: Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Metabolic Diseases

1 pipeline

Marketed

Pipeline